ABSTRACT
Objective This audit examines the impact of a recently-commissioned clinician and patient support tool, on care pathways for Inflammatory Bowel Disease patients at Milton Keynes University Hospital, on follow up appointments (including PIFUs), associated cost savings and patient and clinician engagement and experience.
Design The audit was conducted using a retrospective, consecutive case review of appointment records of patients enrolled onto the iOWNA platform during a 9-month audit period. Patient-clinician interactions were categorised depending on whether an appointment was saved and an appropriate nursing time saving logged. Data on both cost savings and PIFU numbers were also collected from the trust. Quantitative and qualitative feedback of clinician and patient experience were captured.
Results The deployment of iOWNA resulted in a total time saving of 14,735 minutes across the audit period, of which 9,280 minutes comprised savings on in-person appointments, representing 232 appointments saved. The cost savings for these 232 replaced appointments totalled 16,704 GBP. The audit period also saw a statistically significant (p<0.01) increase in the number of Patient-Initiated Follow Ups (PIFUs). Patient and clinician surveys reflected positive experiences of the new care pathway among all service users.
Conclusion The results of the audit demonstrate the important role digital tools can play in transforming existing care pathways to deal with the widespread challenges facing the NHS following the COVID-19 pandemic, with annual savings of over 345 million GBP for the NHS if the appointment cost savings demonstrated in this audit were replicated alongside a 5% reduction nationally in outpatient attendances.
What is already known on the topic
The deployment of evidenced-based digitally-enabled care pathways for Inflammatory Bowel Disease (IBD) is scarce. Traditional pathways are maintained, with patient education during appointments being time-consuming for clinicians and ineffective for patients, resulting in patients forgetting large amounts of what has been communicated to them and not being able to self-manage their condition optimally.
Leveraging technology has been acknowledged as an important tool for patient empowerment thus aiding patient self-management, which will play an important role in the recovery of elective care services in the wake of the disruption caused by the COVID-19 pandemic.
What this study adds
We report the results of a clinical audit on the impact of a commissioned clinician and patient support tool, iOWNA, on existing IBD care pathways at Milton Keynes University Hospital 2023.
How this may affect research, practice or policy
The clinical evidence from the audit demonstrates that digital transformation of chronic disease care pathways is an effective means of improving the delivery of outpatient care, offering advantages in terms of cost, clinician experience, and patient experience.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Oxford A NHS Research Ethics Committee confirmed that as a clinical audit, ethical approval was not required for this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
